COGT
Cogent Biosciences, Inc.
$32.67
+0.09
(+0.28%)
Mkt Cap
5.58B
Volume
1,861,865
52W Range
4.795-43.73
Sector
Healthcare
Beta
0.37
EPS (TTM)
-3.08
P/E Ratio
-7.30
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 7.87M | 22.50M | 9.73M | 8.36M | 6.36M | 2.99M |
| Net Income | (328.94M) | (255.86M) | (192.41M) | (140.24M) | (72.27M) | (74.81M) | (30.27M) | (34.53M) | (25.49M) | (18.12M) | (6.59M) |
| EPS | -2.55 | -2.46 | -2.42 | -2.26 | -1.85 | -6.00 | -3.97 | -5.55 | -3.45 | -3.10 | -1.13 |
| Free Cash Flow | (266.00M) | (208.36M) | (156.42M) | (125.50M) | (60.48M) | (35.85M) | (41.55M) | (33.04M) | (26.75M) | (21.95M) | N/A |
| FCF / Share | -3.93 | -2.01 | -1.96 | -2.14 | -1.56 | -3.24 | -5.45 | -5.31 | -3.62 | -3.75 | N/A |
| Operating CF | (264.44M) | (207.79M) | (153.62M) | (118.64M) | (58.76M) | (35.85M) | (41.51M) | (32.49M) | (25.84M) | (18.64M) | N/A |
| Total Assets | 937.61M | 327.90M | 313.44M | 300.81M | 232.09M | 250.92M | 49.42M | 85.93M | 49.12M | 75.55M | N/A |
| Total Debt | 253.15M | 17.47M | 18.85M | 19.65M | 3.15M | 5.21M | 6.03M | 0 | 0 | 0 | N/A |
| Cash & Equiv | 312.01M | 98.17M | 53.23M | 139.89M | 219.68M | 242.19M | 37.42M | 55.67M | 28.27M | 41.32M | N/A |
| Book Value | 636.37M | 256.29M | 257.80M | 255.74M | 214.18M | 234.67M | 31.76M | 60.23M | 28.30M | 52.39M | N/A |
| Return on Equity | -0.52 | -1.00 | -0.75 | -0.55 | -0.34 | -0.32 | -0.95 | -0.57 | -0.90 | -0.35 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (97.35M) | (102.49M) | (80.93M) | (73.53M) | (71.99M) | (67.93M) | (70.63M) | (58.95M) | (58.35M) | (54.37M) | (55.38M) | (44.08M) |
| EPS | -0.60 | -1.13 | -0.71 | -0.64 | -0.52 | -0.61 | -0.64 | -0.59 | -0.62 | -0.63 | -0.64 | -0.59 |
| Free Cash Flow | (87.33M) | (79.92M) | (64.35M) | (54.67M) | (67.06M) | (60.65M) | (52.26M) | (42.85M) | (52.60M) | (44.38M) | (38.09M) | (33.32M) |
| FCF / Share | -1.30 | -1.18 | -0.56 | -0.48 | -0.59 | -0.55 | -0.47 | -0.43 | -0.55 | -0.51 | -0.44 | -0.45 |
| Operating CF | (86.88M) | (79.11M) | (64.29M) | (54.54M) | (66.51M) | (60.58M) | (51.98M) | (42.70M) | (52.53M) | (44.07M) | (37.97M) | (32.07M) |
| Total Assets | 903.01M | 937.61M | 425.93M | 274.82M | 283.80M | 327.90M | 384.02M | 429.94M | 476.11M | 313.44M | 355.45M | 392.37M |
| Total Debt | 238.65M | 253.15M | 60.56M | 60.66M | 17.09M | 17.47M | 17.83M | 18.18M | 18.52M | 18.85M | 19.17M | 19.36M |
| Cash & Equiv | 241.21M | 312.01M | 125.30M | 127.60M | 126.00M | 98.17M | 97.05M | 88.22M | 215.80M | 53.23M | 86.81M | 214.32M |
| Book Value | 607.69M | 636.37M | 302.46M | 155.04M | 219.00M | 256.29M | 314.66M | 373.22M | 422.33M | 257.80M | 302.90M | 348.43M |
| Return on Equity | -0.16 | -0.16 | -0.27 | -0.47 | -0.33 | -0.27 | -0.22 | -0.16 | -0.14 | -0.21 | -0.18 | -0.13 |
COGT News
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy'
Head to Head Contrast: Cogent Biosciences (NASDAQ:COGT) versus GT Biopharma (NASDAQ:GTBP)
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding